ARCBCI™ is our investigational system that pairs ARCIM® Therapy with a brain-computer interface (BCI) to restore thought-driven movement of the upper and lower limbs.
Meet Gert-Jan and learn about his journey
ARCBCI
The ARCBCI System creates a “digital bridge,” reconnecting communication between the brain and the body to restore thought-driven movement after paralysis.
The ARCBCI System uses artificial intelligence (AI) to decode a person’s brain signals and translate their intention to move into precise stimulation instructions for the ARCIM System.
The US FDA awarded Breakthrough Device Designation to the ARCBCI System in early 2024.
In partnership with EPFL and CEA-Clinatec, in 2021 we successfully implanted an investigational BCI in a human to augment our ARCIM Therapy with thought-driven movement of the legs after paralysis. The approach was published in Nature in May 2023.
With a European Innovation Council grant to study restoration of thought-driven arm and hand movement after SCI, an additional human was implanted with ARCIM Therapy + BCI in 2023. Three more people are scheduled to participate in the study in 2024.
The ARCBCI System creates a “digital bridge,” reconnecting communication between the brain and the body to restore thought-driven movement after paralysis.
The ARCBCI System uses artificial intelligence (AI) to decode a person’s brain signals and translate their intention to move into precise stimulation instructions for the ARCIM System.
The US FDA awarded Breakthrough Device Designation to the ARCBCI System in early 2024.
In partnership with EPFL and CEA-Clinatec, in 2021 we successfully implanted an investigational BCI in a human to augment our ARCIM Therapy with thought-driven movement of the legs after paralysis. The approach was published in Nature in May 2023.
With a European Innovation Council grant to study restoration of thought-driven arm and hand movement after SCI, an additional human was implanted with ARCIM Therapy + BCI in 2023. Three more people are scheduled to participate in the study in 2024.
All ONWARD® Medical devices and therapies referenced here, including but not limited to ARCIM®, ARCEX®, ARCBCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.